Compare Ginkgo Bioworks Holdings Inc (DNA) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Marathon Petroleum Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.02 (market cap $763.64M), while Marathon Petroleum Corp trades at $462.3 (market cap $130.12B). The key difference: Marathon Petroleum Corp is far larger — about 170.4× Ginkgo Bioworks Holdings Inc's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Marathon Petroleum Corp for 54 Days on average.
| DNA | MPC | |
|---|---|---|
Market Cap | $763.64M | $130.12B |
Volume | 3,204,177 | 2,749,647 |
Sector | Health | Energy |
52-Week High | $15.83 | $463.34 |
52-Week Low | $5.48 | $162.63 |
Typical Hold Time | 7 Days | 54 Days |
Enterprise Value | $865.59M | $156.64B |
Dividend Yield | — | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
Marathon Petroleum (MPC) trades at $442.26, up 2.29% today, reflecting strong momentum amid bullish technical signals and recent earnings beats. The stock shows robust profitability with a 47.9% ROE and trades at a P/E of 16.07, below the sector average. Recent news highlights refining margin strength and positive analyst sentiment, though risks include potential diesel export restrictions and volatile energy markets.
Outlook remains positive with 75.8% of analysts rating it a buy and a consensus price target of $420.30. Key opportunities include elevated refining margins and solid cash flow, while risks involve regulatory uncertainty and cyclical demand pressures. The stock's valuation and growth prospects support a constructive view for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
